Article
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.
Lancet (London, England) - 16 Oct 2010
Mega Jessica L, Close Sandra L, Wiviott Stephen D, Shen Lei, Walker Joseph R, Simon Tabassome, Antman Elliott M, Braunwald Eugene, Sabatine Marc S
Abstract excerpt
BACKGROUND: Clopidogrel and prasugrel are subject to efflux via P-glycoprotein (encoded by ABCB1, also known as MDR1). ABCB1 polymorphisms, particularly 3435C→T, may affect drug transport and efficacy. We aimed to assess the effect of this polymorphism by itself and alongside variants in CYP2C19...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.